Christopher Cantrill, MD
Urology · San Antonio, TXNPI 1568642296
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 89.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $25,531 and has fallen 98.3% since, to $437 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 138 payments — averaging $532.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$66K
- Procept Biorobotics Corporation$6K
- Olympus America Inc.$240
- Medtronic$188
- Johnson & Johnson$179
- Ferring Pharmaceuticals Inc.$125
- plus $791 from 13 others
Across 33 payments — averaging $8328.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$237K
- GSK$22K
- Laborie Medical Technologies Corp.$5K
- Urotronic, Inc$5K
- Urovant Sciences Inc$5K
- Sumitomo Pharma America, Inc.$1K
What the payments were for
- Consulting fees$29,60240%
- Speaking & faculty fees$32,65044%
- Travel & lodging$6,9189%
- Food & beverage$4,2326%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 91 | $65,794 |
| Procept Biorobotics Corporation | 13 | $6,120 |
| Olympus America Inc. | 4 | $240 |
| Medtronic | 1 | $188 |
| Johnson & Johnson | 2 | $179 |
| Ferring Pharmaceuticals Inc. | 4 | $125 |
| Angiodynamics, Inc. | 1 | $119 |
| Coloplast | 1 | $110 |
| Sumitomo Pharma America, Inc. | 4 | $107 |
| Blue Earth Diagnostics | 4 | $92 |
| Astellas Pharma US Inc | 5 | $87 |
| Progenics Pharmaceuticals, Inc. | 1 | $65 |
| Cook Medical LLC | 1 | $59 |
| Photocure Inc | 1 | $38 |
| AstraZeneca | 1 | $35 |
| Urogen Pharma, Inc. | 1 | $35 |
| Teleflex LLC | 1 | $18 |
| Antares Pharma, Inc. | 1 | $14 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZUM$32,022
- GENERAL BPH$19,385
- rezum Generator$6,050
- GENERAL - THERAPIES$4,603
- AQUABEAM SYSTEM$4,127
- AquaBeam Robotic System$1,838
- SPACEOAR$800
- GENERAL VASCULAR ACCESS$600
- GENERAL PAIN MANAGEMENT$359
- UROMAX$350
- INTERSTIM$188
- Erleada$150
- TACTRA$148
- AdVance XP$142
- iTIND System$136
- Nanoknife$119
- SUPRIS$110
How this compares
$73,437 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 212 | $199,252 |
| GemtesaVibegron | 58 | $71,638 |
| OrgovyxRelugolix | 14 | $38,098 |
| Mirabegron ErMirabegron | 15 | $12,170 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 341 | $9,333 |
| Tamsulosin Hcl | 544 | $6,217 |
| Estradiol | 58 | $5,536 |
| Finasteride | 359 | $4,402 |
| Solifenacin Succinate | 40 | $3,225 |
| Testosterone Cypionate | 36 | $2,071 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,300 |
| Oxybutynin Chloride ErOxybutynin Chloride | 60 | $867 |
| Dutasteride | 15 | $386 |
| Silodosin | 11 | $275 |
| Allopurinol | 15 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $87 | $199,252212 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $107 | $109,73572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in San Antonio
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jose de la CerdaSan Antonio$278K
- Naveen KellaSan Antonio$84K
- Robert SvatekSan Antonio$51K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.